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AIMS
Urocortin 2 and urocortin 3 may play a role in the pathophysiology of heart failure and are emerging therapeutic targets. We
aimed to examine the local and systemic cardiovascular effects of urocortin 2 and urocortin 3 in healthy subjects and patients with
heart failure.
METHODS
Patients with heart failure (n = 8) and age and gender-matched healthy subjects (n = 8) underwent bilateral forearm arterial blood
ﬂow measurement using forearm venous occlusion plethysmography during intra-arterial infusions of urocortin 2 (3.6–
36 pmol min1), urocortin 3 (360–3600 pmol min1) and substance P (2–8 pmol min1). Heart failure patients (n = 9) and healthy
subjects (n = 7) underwent non-invasive impedance cardiography during incremental intravenous infusions of sodium nitro-
prusside (573–5730 pmol kg1 min1 ), urocortin 2 (36–360 pmol min1 ), urocortin 3 (1.2–12 nmol min1) and saline placebo.
RESULTS
Urocortin 2, urocortin 3 and substance P induced dose-dependent forearm arterial vasodilatation in both groups (P < 0.05 for
both) with no difference in magnitude of vasodilatation between patients and healthy subjects. During systemic intravenous in-
fusions, urocortin 3 increased heart rate and cardiac index and reduced mean arterial pressure and peripheral vascular resistance
index in both groups (P < 0.01 for all). Urocortin 2 produced similar responses to urocortin 3, although increases in cardiac index
and heart rate were only signiﬁcant in heart failure (P < 0.05) and healthy subjects (P < 0.001), respectively.
CONCLUSION
Urocortins 2 and 3 cause vasodilatation, reduce peripheral vascular resistance and increase cardiac output in both health and
disease. These data provide further evidence to suggest that urocortins 2 and 3 continue to hold promise for the treatment of
heart failure.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Urocortins 2 and 3 are emerging therapies for treating heart failure.
• Urocortins 2 and 3 reduce peripheral vascular resistance and increase cardiac output in both health and disease.
WHAT THIS STUDY ADDS
• This is the ﬁrst direct head-to-head comparison of urocortin 2 and urocortin 3 in man.
• These data provide further evidence that urocortin 2 and urocortin 3 hold major potential for the treatment of heart
failure.
Introduction
There are almost sixmillion people living with heart failure in
the USA. This comes at an annual cost to the US economy of
over $30 billion [1]. Despite many evidence-based therapies
for patients with chronic heart failure, treatments for acute
heart failure are limited, less well developed and have not
been shown to improve clinical outcomes. Indeed the use of
inotropic agents has been associated with harm [2–4]. How-
ever, the tentative but promising improvements in clinical
outcome seen with serelaxin in the recent RELAX-AHF study
[5] has renewed enthusiasm for the assessment of novel vaso-
active mediators in this important patient group.
The urocortins are an endogenous peptidic hormone
group comprising urocortin 1, urocortin 2 and urocortin 3
with vasodilator, inotropic and lusitropic effects [6].
Urocortins 2 and 3 counteract many of the effects of
corticotrophin-releasing hormone (CRH) [7–10] and act on
the CRH-receptor 2 (CRH-R2), a G-protein coupled receptor
that is expressed abundantly in the heart and peripheral vas-
culature [11, 12]. Urocortin 2 causes vasodilatation in healthy
volunteers, augments cardiac output and reduces vascular re-
sistance in healthy humans, patients with acute decompen-
sated, and also chronic stable, heart failure [13–16].
A recombinant acetate salt of urocortin 3 (JNJ-39 588 146
[recombinant stresscopin]), improved cardiac output whilst
reducing vascular resistance in amulticentre study of patients
with chronic stable heart failure [17]. We recently demon-
strated that urocortins 2 and 3 increase forearm blood ﬂow
in young healthy volunteers [15]. To date, no clinical study
has separated the regional from systemic effects of urocortins
2 and 3 in heart failure or conducted a direct head to head
comparison of their effects.
We aimed to evaluate and compare the local and systemic
cardiovascular effects of urocortins 2 and 3 in patients with
heart failure and healthy subjects by assessing (i) local fore-
arm arterial blood ﬂow using venous occlusion plethysmog-
raphy and (ii) cardiac output and vascular resistance using
thoracic bioimpedance cardiography. We hypothesized that
urocortins 2 and 3 would cause vasodilatation, reduced pe-
ripheral vascular resistance and increased cardiac output in
both healthy subjects and patients with heart failure.
Methods
Both studies were approved by the local research ethics com-
mittee (South East Scotland REC 01) and carried out in accor-
dance with the Declaration of Helsinki. The registered clinical
trials on UKCRN were ID 10749 and 13002.
Written informed consent was obtained from all partici-
pants prior to the study.
Study participants
Patients with heart failure were eligible if they were aged 18–
80 years, New York Heart Association (NYHA) symptom
class II–III and had echocardiographically conﬁrmed left
ventricular ejection fraction <35% with left ventricular
end diastolic diameter > 5.5 cm. Patients were required to
be receiving maximally tolerated doses of angiotensin-
converting enzyme inhibitor and β-adrenoceptor blocker
therapies for at least 3 months. Healthy subjects had no sig-
niﬁcant previous medical history and were on no regular
medications. Exclusion criteria for both groups included
systolic blood pressure > 190 mmHg or <90 mmHg, haemo-
dynamically signiﬁcant valvular heart disease and other
severe or signiﬁcant co-morbidities including bleeding
diathesis, renal or hepatic failure, anaemia or recent
infective/inﬂammatory conditions. Women of child bearing
potential were also excluded.
Protocol A: local vascular study
This was a randomized study (Figure 1A) of eight patients
with heart failure and eight age and gender-matched healthy
subjects. Subjects attended once each to receive incremental
intra-arterial infusions of urocortin 2 (3.6, 12, 36 pmolmin1,
molecular weight 4450.3 g mol1), urocortin 3 (360, 1200,
3600 pmol min1, molecular weight 4137.9 g mol1) and
substance P (2, 4, 8 pmol min1 [control endothelium-
dependent vasodilator]) for 6 min at each dose with a
30 min washout period between agents.
Forearm venous occlusion plethysmography studies were
performed with the subject lying supine, in a quiet,
temperature-controlled room (22–25°C). Participants fasted
for 4 h prior to the study and refrained from alcohol and caf-
feine for 24 h prior to the study. Venous cannulae (17G) were
inserted into large subcutaneous veins in the antecubital fos-
sae of both arms at the start of the study to facilitate periodic
venous sampling. Heart rate and blood pressure were moni-
tored at regular intervals throughout the study with a semi-
automated oscillometric sphygmomanometer (Omron
705IT). Participants underwent brachial artery cannulation
of the non-dominant forearm with a 27 standard wire-gauge
steel needle for agent infusion. Forearm blood ﬂow was mea-
sured in the infused and non-infused forearms using bilateral
venous occlusion plethysmography as described previously
[18, 19].
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Protocol B: systemic study
This was a randomized, double-blind, placebo controlled
crossover study (Figure 1B). Three patients with heart failure
and three volunteers participants were involved in both stud-
ies. Patients with heart failure (n = 9) and healthy subjects
(n = 7) were recruited. Participants had venous cannulae
inserted into both antecubital fossae and attended on two oc-
casions, receiving intravenous infusions of saline (placebo) or
SNP (573, 1909, 5730 pmol kg1 min1) followed by either
urocortin 2 (36, 108, 360 pmol min1) or urocortin 3 (1.2,
3.6, 12 nmol min1). On the second visit, participants re-
ceived the two remaining agents not administered on visit
1. Each agent was given in three ascending doses for 10 min
at each dose. A 1 h saline washout was given between agents
and a further 30min of saline washout was administered after
the cessation of the second agent.
Haemodynamic monitoring. Haemodynamic measurements
were recorded throughout the study. Cardiac output, blood
pressure and stroke volume were recorded using non-
invasive thoracic impedance cardiography (NCCOM3-R7,
BioMed, CA, USA or Cardioscreen 1000, Medis, Germany)
and oscillometric sphygmomanometry (Omron HEM-
705CP, Omron, Matsusaka, Japan). Values were indexed to
body surface area where appropriate and peripheral
vascular resistance index was calculated using recorded
measurements (PVRI = MAP/CI).
Safety. Study stopping criteria were in place to ensure
participant safety. Criteria included a drop in diastolic blood
pressure of >25 mmHg, fall in heart rate below
50 beats min1 or rise above 120 beats min1, at the request
of the participant, attending nurse or the attending
physician.
Venous sampling. Baseline blood samples were drawn for
assessment of full blood count, renal function, glucose and
cholesterol concentrations at the start of each study. The
local clinical biochemistry and haematology reference
laboratories performed analysis.
Data analysis and statistics. Data were collected in a double-
blind fashion for both studies. Data were analyzed, where
appropriate, by analysis of variance (ANOVA, one way and
two way with repeated measures where appropriate). All
results in ﬁgures are expressed as mean ± SEM. All statistical
analysis was performed with GraphPad Prism, version 6
(GraphPad Software, San Diego, CA, USA). Statistical
signiﬁcance was taken as two-sided P < 0.05.
Figure 1
A) Schematic representation of study protocol A – vascular study and B) schematic representation of study protocol B – systemic study. A) forearm
blood ﬂow. B) systemic haemodynamic responses
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Results
Patients with heart failure and healthy subjects recruited
were predominantly male and middle-aged. Heart failure
patients had greater BMI compared with healthy subjects.
Participant characteristics are shown in Table 1. Patients with
heart failure were receiving maintenance heart failure ther-
apy. Patients and volunteers were age and gender-matched
in protocol A and age matched alone in protocol B. Three pa-
tients with heart failure and three volunteer participants were
recruited to both studies.
Protocol A – vascular study
The intra-brachial infusion of all three drugs was well
tolerated with no adverse effects. Intra-brachial infusion of
urocortin 2 and 3 produced localized, self-limiting forearm
ﬂushing and some facial ﬂushing in both groups of partici-
pants as noted in previous studies [15].
Urocortin 2, urocortin 3 and substance P all evoked dose-
dependent forearm arterial vasodilatation in both participant
groups (mean changes across the three doses [95% CI] from
baseline as follows: urocortin 2 +60% [9–111] P < 0.05,
+72% [21–123] P < 0.01; urocortin 3 +167% [100–237]
P < 0.0001, +151% [82–219] P < 0.0001; substance P +227%
[130–326] P < 0.0001, +155% [57–253] P < 0.001 for healthy
controls and heart failure patients, respectively; Figure 2A).
There were no signiﬁcant differences in changes in forearm
blood ﬂow between heart failure patients and healthy
subjects (urocortin 2 +12% [40 to 63%] P = 0.84, urocortin
3 18% [86 to +50%], P = 0.80; substance P 72%
[170  +26%] P + 0.19).
Blood pressure and heart rate remained unchanged in
both groups in response to urocortin 2 and substance P. At
the highest dose, urocortin 3 induced a transient tachycardia
compared with baseline in both groups (heart failure
+14.9 beats min1 [20.9 to 8.9], healthy volunteers
+21.3 mmHg [27.3 to 15.3] both P < 0.0001) that was accom-
panied by a drop in systolic (17.4 mmHg [7.9 to 26.9],
P < 0.0001) and diastolic blood pressure in patients with
heart failure (8.4 mmHg [3.5 to 13.3], P < 0.001) and a
drop in diastolic blood pressure alone in healthy subjects
(12.4 mmHg [7.5 to 17.3], P < 0.0001, Figure 2B).
Non-infused forearm blood ﬂow remained unchanged
throughout the study (data not shown).
Protocol B – systemic study
Participants displayed hypotension at the higher doses of
SNP initially administered in the study (17.2 nmol
kg1 min1), frequently reaching study stopping criteria. A
dose reduction to SNP (maximum dose of 5730 pmol-
kg1 min1) was made after two healthy subjects completed
the study. For the urocortins, hypotension reaching study
stopping criteria was met in one heart failure patient for
urocortin 2 and two heart failure patients and one healthy
subject for urocortin 3. Participants described dose-
dependent symptoms of tachycardia and a warm sensation
with both urocortins, but there were no signiﬁcant adverse
events attributable to either urocortin 2 or urocortin 3. Full
blood count and serum biochemistry was unchanged
between the two study visits (Table 1).
Urocortin 2 had no signiﬁcant effect on cardiac index in
healthy subjects and heart rate in heart failure patients when
compared with saline placebo (P > 0.05 for both, see Figure 3
Table 1
Participant characteristics for protocol A and B
Protocol A Protocol B
Heart failure




patients (n = 9)
Healthy subjects
(n = 7)
Age (years) 55.5 [52.25–67] 57 [53–65.75] P = 0.84 58 [50–66.5] 58 [45–66] P = 0.56
BMI 30 ± 5.4 25.1 ± 2.3 P = 0.03 32.2 ± 4.3 25.9 ± 1.9 P = 0.003
Gender 5 M, 3F 5 M, 3F 7 M, 2F 4 M, 3F
ACEi/ARB 8 (100) n/a 9 (100) n/a
BB 6 (75) n/a 7 (78) n/a
MRA 5 (63) n/a 8 (89) n/a
Digoxin 1 (13) n/a 4 (44) n/a
Loop diuretic 6 (75) n/a 6 (67) n/a
Haemoglobin
(visit 1 vs visit 2, g l1)
n/a n/a 136.0 ± 14.46 vs
133.0 ± 14.96
(P > 0.99)
143.7 ± 7.111 vs
135.3 ± 8.524
(P > 0.99)
Creatinine (visit 1 vs
visit 2, μmol l1)
n/a n/a 109.8 ± 39.66 vs
116.3 ± 74.95
(P > 0.99)
75.29 ± 8.635 vs
72.67 ± 7.840
(P > 0.99)
n (%), mean ± SD, median [interquartile range]
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and Table 2 for results). Otherwise urocortin 2 and urocortin
3 increased cardiac index and heart rate and reduced mean
arterial pressure and peripheral vascular resistance index in
both patients with heart failure and healthy subjects
(P < 0.05 for all). There was no effect of either urocortin 2 or
urocortin 3 on stroke volume (P > 0.05 for both).
At the doses used, urocortin 3 caused greater mean in-
creases than urocortin 2 in cardiac index (+13.4 [+4.1 to
+22.6], P < 0.01) and heart rate (+11.0 [+2.9 to +19.2],
P < 0.01) and greater mean reductions in mean arterial
pressure (+4.4 [0.0 to +8.7], P < 0.05) and peripheral vascular
resistance index (+11.2 [2.2 to +20.1], P < 0.01) in patients
with heart failure. No such haemodynamic differences
existed between urocortin 2 and urocortin 3 in healthy
subjects. No haemodynamic differences existed between
participant groups for both urocortin 2 and urocortin 3
(P > 0.05 for all). Following cessation of the intravenous
infusions, haemodynamic variables returned to baseline after
40–60 min (for example, cardiac index, Figure 4). Over the
infusion and washout period, urocortin 3 again caused a
greater increase in cardiac output (P < 0.0001) than urocortin
2 in patients with heart failure but not in healthy subjects
(P = 0.48).
Discussion
For the ﬁrst time, we report the local vascular and systemic
effects of urocortins in both patients with heart failure and
healthy subjects. We demonstrate that both urocortin 2
and urocortin 3 increase cardiac index and reduce periph-
eral vascular resistance and their parenteral administration
is feasible, safe and well tolerated. We conclude this haemo-
dynamic proﬁle suggests that urocortins 2 and 3 hold major
potential for the treatment of acute heart failure.
Forearm venous occlusion plethysmography combined
with intra-arterial cannulation allows the assessment of local,
sub-systemic vasomotor effects of peptides without exerting a
systemic response. This is particularly useful in the study of
novel compounds, such as urocortin 2 and urocortin 3. We
have previously demonstrated that urocortin 2 and 3 cause
vasodilatation in healthy subjects and that is in part medi-
ated by endothelium-dependent factors such as nitric oxide
and endothelium derived hyperpolarizing factor [15]. Im-
paired endothelial function is a recognized feature and an in-
dependent predictor of adverse outcome in patients with
heart failure [20–24]. There is therefore a theoretical concern
that urocortin would be less effective in patients with heart
failure because of this concomitant endothelial dysfunction.
However, we demonstrate that urocortin 2 and urocortin 3
evoked normal forearm arterial vasodilatory responses in
our patients with heart failure. This suggests that either
endothelial dysfunction does not have a meaningful impact
on the actions of urocortin or our subjects did not have
signiﬁcant endothelial dysfunction. Interestingly, our pa-
tients did not demonstrate impaired substance P induced
vasodilatation suggesting preserved endothelial function.
This may reﬂect that the patients studied had stable heart
Figure 2
Haemodynamic responses during local administration of urocortin 2, urocortin 3 and substance P (protocol A). A) Percentage change in forearm
arterial blood ﬂow to urocortin 2 (3.6–36 pmol min1), urocortin 3 (360–3600 pmol min1) and substance P (2–8 pmol min1) in patients with
heart failure (red) and in healthy subjects (black). B) Non-invasive systemic hemodynamic responses to intra-arterial urocortin 2 (red), urocortin 3
(blue) and substance P (green) in healthy subjects (A) and patients with heart failure (B). (**** = P,0.0001,** = P < 0.01, * = P < 0.05)
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failure symptoms and were well-treated and receiving opti-
mal medical therapy. Whether similar ﬁndings would be ob-
served in patients with decompensated heart failure remains
to be established.
During local intra-arterial infusions of the urocortins, we
were not anticipating observing any major changes in
haemodynamic variables in either group. However, we found
dose-related increases in heart rate and falls in diastolic blood
pressure, especially with urocortin 3 in healthy subjects. This
suggests that at the doses used here, we had systemic spill
over of urocortin such that we achieved vasoactive blood
concentrations outwith the forearm. The doses where
systemic systemic spill over was seen helped guide the dosing
regime used in protocol B. We have seen systemic spill over
previously with other compounds such as substance P [25]
and this is heralded by systemic ﬂushing and rises in the
contralateral non-infused forearm blood ﬂow. However, here
we observed no change in contralateral non-infused forearm
Figure 3
Changes in haemodynamic responses from baseline following systemic infusion (protocol B). Haemodynamic responses to infusions of urocortin
2, urocortin 3 and SNP in healthy subjects (black) and patients with heart failure (red) at doses 1–3 (D1–D3). * represents signiﬁcant differences
from saline placebo (not shown) across the three doses (see Table 2). ^ represents signiﬁcant differences between participant groups.
(****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05; ^^P < 0.01)
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blood ﬂow although subjects did develop some skin ﬂushing.
This suggests that other vascular beds, such as the dermal and
splanchnic circulation, are more sensitive to the actions of
the urocortins than the forearm circulation. The increase in
heart rate at the highest dose of urocortin 3 was less
pronounced in patients with heart failure and this was likely
due to concomitant β-adrenoceptor blocker therapy. Further-
more the associated lower systolic and diastolic blood
pressures in this group may be explained by a relative lack
of compensatory tachycardia response to vasodilatation in
these patients.
During systemic intravenous infusions, we observed in-
creases in cardiac output with both urocortins. This increase
in cardiac output is likely to occur in response to the systemic
vasodilatation induced by the urocortins. Although there was
no change in stroke volume for either urocortin, this is not a
direct measurement of inotropy and we cannot exclude a
direct inotropic effect of urocortin on the heart, as previously
seen with urocortin 2 in rodents [26]. At the doses we admin-
istered, urocortin 3 exerted more marked haemodynamic
effects than urocortin 2 in patients but not healthy subjects.
This may reﬂect the differences in doses we employed, but
may also reﬂect important differences between these two
agents. This needs further exploration to determine which
urocortin subtype is themost promising for clinical therapeu-
tic development.
Differences in biological effects between the urocortins
can be explained by the structural differences that exist
between the two agents, generating conformational changes
in the G protein coupled receptor, in turn altering secondary
messenger systems that are responsible for creating the
biological effects seen. However it may not be this simple
and there may be other systems involved. Promising preclin-
ical studies suggest a role for the urocortins in the inhibition
Table 2
Results of systemic infusion of urocortin 2 and 3
Urocortin 2 Urocortin 3 SNP
Healthy volunteers
Cardiac index +11.9 [3.1, +26.9] P = 0.17 +25.4 [+9.8, +41.0]*** +21.7 [+5.5, +37.8]**
Heart rate +17.2 [+7.2, +27.1]*** +25.0 [+14.7, +35.4]**** +29.0 [+18.4, +39.8]****
MAP 8.0 [2.6, 13.5]** 10.8 [5.1, 16.4]**** 13.0 [7.2, 18.8]****
SV 3.7 [13.8, +6.4] P = 0.77 6.3 [16.9, +4.2] P = 0.40 6.8 [17.4, +3.9] P = 0.35
PVRI 17.6 [3.5, 31.7]** 23.1 [8.4, 37.8]*** 22.1 [6.9, 37.3]**
Heart failure
Cardiac index +10.1 [+1.0, +19.3]* +23.5 [+14.3, +32.7]**** +14.2 [+3.8, +24.7]**
Heart rate +7.1 [0.8, +15.0] P = 0.1 +18.1 [+10.0 , +26.3]**** +7.4 [1.8, +16.6] P = 0.16
MAP 4.8 [0.5, 9.0]* 9.1 [4.8, 13.5]**** 13.6 [8.7, 18.5]****
SV +2.7 [2.4, +7.8] P = 0.51 +4.3 [0.9, +9.5] P = 0.14 +0.7 [4.8, +6.3] P = 0.99
PVRI 14.0 [5.3, 22.7]*** 25.2 [16.2, 34.2]**** 22.1 [12.2, 32.0]****
Mean difference [95% CI] of each agent with saline placebo across the three administered doses. * represents signiﬁcant differences from
placebo. ( ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05).
Figure 4
Duration of haemodynamic response (min) to intravenous urocortin 2 and urocortin 3 (protocol B). Effects of urocortin 2 (red) and urocortin 3
(blue) last 40–60min after cessation of dose 3 (D3) before returning to baseline. At the doses used, urocortin 3 caused a greater increase in cardiac
output compared with urocortin 2 in patients with heart failure (P < 0.0001) but not healthy subjects (P = 0.48)
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of cardiac sympathetic nerve activity [SNA] [27, 28], often
overactive in patients with heart failure. Although Ucn2 has
been reported to increase skeletal muscle SNA in humans
[29], this should not necessarily be seen as a discrepant ﬁnd-
ing as SNA responses typically are regionally differentiated.
Increases in heart rate have not been reported in recent
studies with urocortin 2/stresscopin [16, 17]. However higher
doses of urocortin 2 [14], comparable with the doses we have
used here, saw similar increases in heart rate.
There may be concern regarding the clinical use of a heart
failure therapy that is both positively chronotropic and ino-
tropic. This combination of effects might predispose to in-
creased myocardial oxygen consumption and potential
arrhythmia, particularly in patients with coronary artery dis-
ease. We observed no episodes of arrhythmia or adverse ef-
fects in our study and, indeed, urocortin 2 has been shown
to have anti-arrhythmic effects that would be hugely beneﬁ-
cial in treating this group of patients [30, 31]. However, our
infusions were brief and adverse effects may be seen with lon-
ger infusions or in those patients with decompensated heart
failure. In addition, avoidance of signiﬁcant hypotension re-
mains an important consideration, especially in patients
with already low perfusion pressure or renal impairment. Re-
sults from our study suggest that dose titration during admin-
istration may be needed to optimize cardiac output and
vasodilatory responses, whilst avoiding the unwanted effects
of signiﬁcant tachycardia or hypotension.
Study limitations
This study included only patients with stable heart failure
who were prescribed evidence-based heart failure therapy
that may have affected the response of these agents. However,
there was no evidence of diminished effect with concomitant
medical therapy in patients with heart failure. We did not
include patients with acute decompensated heart failure but
we did compare with healthy control subjects, not used in a
similar sized study with urocortin 2 [14]. Although our results
cannot be extrapolated to the setting of acute heart failure,
there appears to be no reason why the beneﬁcial effects seen
in this study cannot be replicated in the acute heart failure
setting provided an appropriate, controlled dosing regime is
used. Furthermore studies using urocortin 2, and derivatives
thereof, in the acute setting have already been carried out
successfully. There does however remain a clear need for
urocortin 3 to be trialled in this group of patients.
We observed increases in cardiac index in protocol B but
it should be reinforced that this study was not designed to
compare the relative contributions of chonotropy, inotropy
and vasodilatation to the changes in cardiac index we
recorded. Invasive studies would be required for this.
Furthermore, the molar concentrations of urocortin 2 and
urocortin 3 at each dose were different and differences in
efﬁcacy may reﬂect the differences in dose used and not true
differences in potency.
Finally although there was no change in stroke volume for
either agent, we did not conduct invasive haemodynamic
monitoring which would be required for assessment of true
inotropy and also useful for assessment of pulmonary
capillary wedge pressure (PCWP). Surprisingly two recent
studies did not detect a statistically signiﬁcant reduction in
PCWP in patients with heart failure with either urocortin
2/stresscopin [16, 17]. However a clear trend toward a reduc-
tion in PCWP was seen in both studies.
In conclusion, we demonstrate that both urocortin 2 and
urocortin 3 increase cardiac index and reduce peripheral vas-
cular resistance. Their parenteral administration was feasible,
safe and well tolerated. We conclude that these data provide
further evidence suggesting urocortin 2 and urocortin 3 con-
tinue to hold promise for the treatment of heart failure.
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